30 April 2020
Visiongain has launched a new pharma report Global Biosimilars and Follow-On Biologics Market 2020-2030: Monoclonal Antibodies (mAbs), Fusion Proteins, Insulin, Erythropoietin’s, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Growth Hormones, Fertility Hormones, Blood Disorders, Growth Hormone Deficiency, Autoimmune Diseases, Cancer, Diabetes, Infectious Diseases.
Many blockbusters branded innovator drugs are losing patent protection in the coming years. Some have already lost the market exclusivity and hence are prone to share their market space with the generic versions. Some examples include Roche’s Herceptin and Avastin, Amgen’s Enbrel, AbbVie’s Humira, etc. Billions of dollars are at stake for the branded pharmaceuticals market. This has led to a strong push for the biosimilar manufacturers. As such, both established and local pharmaceutical and biotechnology companies are making their way in this potential market.
The lead analyst of the report commented "As mentioned above, rapid growth in the biosimilars market during the period 2020-2030 will be a driven by a wide range of different factors. This will be primarily driven by the demand for lower cost alternatives to biologics by patients, doctors, healthcare payers and nations. Patent expiries for leading branded biologics will allow for the launch of a wider range of biosimilars in both developed and emerging markets."
Leading companies featured in the report include Amgen Inc, Biocon Limited, Celltrion Healthcare Co. Ltd, Dong-A Socio Holdings Co. Ltd, Dr.Reddy's Labs (DRL), F. Hoffmann-La Roche Ltd. and others.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
29 July 2021
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.